FDA
-
-
-
-
-
-
-
Stealth BioTherapeutics to Participate in Upcoming Ultra-Rare Disease Events
-
-
-
-
-
-
-
Stealth BioTherapeutics Granted Pre-NDA Meeting for Elamipretide as a Potential Treatment for Barth Syndrome
-
-
-
-
-
-
-
Stealth BioTherapeutics (MITO) Receives Orphan Drug Designation from FDA for Elamipretide for Treatment of Duchenne Muscular Dystrophy
-
-
-
-
-
-
-
Stealth BioTherapeutics Announces New SBT-272 Data and Trial Initiation
-
-
-
-
-
-
-
Stealth BioTherapeutics to Present at Mitochondria-Targeted Drug Development Summit
-
-
-
-
-
-
-
Stealth BioTherapeutics (MITO) Issues Update On Clinical Stage Rare Disease Programs
-
-
-
-
-
-
-
Stealth BioTherapeutics (MITO) Announces Elamipretide NDA Submission
-
322,899 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

